Impact in brief • 3 min read
An estimated 422 million people worldwide have diabetes. The majority of those live in low-and middle-income countries.
There are approximately 1.5 million deaths directly attributed to the disorder each year. Worryingly, diabetes cases are increasing worldwide.
But innovative pharmaceuticals company Vertex is inching ever closer to a cure for Type 1 diabetes. And a recent Phase I/II trial produced some truly amazing results.
In the clinical study, a patient who was diagnosed with Type 1 diabetes 40 years ago was injected with a single infusion of synthetic insulin-producing cells.
After 90 days, they were able to produce a steady flow of insulin and maintain their insulin production after eating.
Groundbreaking trials like this not only give hope to millions worldwide but likely hit close to home for Vertex’s own Senior Vice President, Gary Meininger.
Gary was diagnosed with Type 1 diabetes at just 19. 30 years later, he is one of the company’s leading physicians responsible for their programs in diabetes and other disorders.
Founded in 1989, Cambridge, Massachusetts-based Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases including diabetes and cistic fibrosis.
The value of your investments can go down as well as up and you may get back less than you originally invested. CIRCA5000 don't offer investment advice, if you're unsure if any investment is right for you please consult a suitably qualified financial adviser. The individual holdings of any fund offered by CIRCA5000 can change without warning.